Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study.

PURPOSE To report the long-term results of 44 keratoconic eyes treated by combined riboflavin ultraviolet A collagen cross-linking in the first Italian open, nonrandomized phase II clinical trial, the Siena Eye Cross Study. DESIGN Perspective, nonrandomized, open trial. METHODS After Siena University Institutional Review Board approval, from September 2004 through September 2008, 363 eyes with progressive keratoconus were treated with riboflavin ultraviolet A collagen cross-linking. Forty-four eyes with a minimum follow-up of 48 months (mean, 52.4 months; range, 48 to 60 months) were evaluated before and after surgery. Examinations comprised uncorrected visual acuity, best spectacle-corrected visual acuity, spherical spectacle-corrected visual acuity, endothelial cells count (I Konan, Non Con Robo; Konan Medical, Inc., Hyogo, Japan), optical (Visante OCT; Zeiss, Jena, Germany) and ultrasound (DGH; Pachette, Exton, Pennsylvania, USA) pachymetry, corneal topography and surface aberrometry (CSO EyeTop, Florence, Italy), tomography (Orbscan IIz; Bausch & Lomb Inc., Rochester, New York, USA), posterior segment optical coherence tomography (Stratus OCT; Zeiss, Jena, Germany), and in vivo confocal microscopy (HRT II; Heidelberg Engineering, Rostock, Germany). RESULTS Keratoconus stability was detected in 44 eyes after 48 months of minimum follow-up; fellow eyes showed a mean progression of 1.5 diopters in more than 65% after 24 months, then were treated. The mean K value was reduced by a mean of 2 diopters, and coma aberration reduction with corneal symmetry improvement was observed in more than 85%. The mean best spectacle-corrected visual acuity improved by 1.9 Snellen lines, and the uncorrected visual acuity improved by 2.7 Snellen lines. CONCLUSIONS The results of the Siena Eye Cross Study showed a long-term stability of keratoconus after cross-linking without relevant side effects. The uncorrected visual acuity and best spectacle-corrected visual acuity improvements were supported by clinical, topographic, and wavefront modifications induced by the treatment.

[1]  Farhad Hafezi,et al.  Corneal Cross-Linking-Induced Stromal Demarcation Line , 2006, Cornea.

[2]  M. Smolek,et al.  Collagen fibril orientation in the human corneal stroma and its implications in keratoconus. , 1997, Investigative ophthalmology & visual science.

[3]  Theo Seiler,et al.  Safety of UVA-Riboflavin Cross-Linking of the Cornea , 2007, Cornea.

[4]  W M Bourne,et al.  Central corneal endothelial cell changes over a ten-year period. , 1997, Investigative ophthalmology & visual science.

[5]  M. Mrochen,et al.  Effect of riboflavin-UVA-induced collagen cross-linking on intraocular pressure measurement. , 2007, Investigative ophthalmology & visual science.

[6]  C. Mazzotta,et al.  Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. , 2006, European journal of ophthalmology.

[7]  Cristina Tommasi,et al.  Treatment of Progressive Keratoconus by Riboflavin-UVA-Induced Cross-Linking of Corneal Collagen: Ultrastructural Analysis by Heidelberg Retinal Tomograph II In Vivo Confocal Microscopy in Humans , 2007, Cornea.

[8]  E. Spörl,et al.  [Biophysical principles of collagen cross-linking]. , 2008, Klinische Monatsblatter fur Augenheilkunde.

[9]  W M Bourne,et al.  Corneal endothelium five years after transplantation. , 1994, American journal of ophthalmology.

[10]  D. Hodge,et al.  Continued endothelial cell loss ten years after lens implantation. , 1994, Ophthalmology.

[11]  C. Mazzotta,et al.  Stromal haze after combined riboflavin‐UVA corneal collagen cross‐linking in keratoconus: in vivo confocal microscopic evaluation , 2007, Clinical & experimental ophthalmology.

[12]  E. Spoerl,et al.  Induction of cross-links in corneal tissue. , 1998, Experimental eye research.

[13]  C. Skorpik,et al.  Altered Organization of Collagen in the Apex of Keratoconus Corneas , 1998, Ophthalmic Research.

[14]  Eberhard Spoerl,et al.  Collagen crosslinking with riboflavin and ultraviolet‐A light in keratoconus: Long‐term results , 2008, Journal of cataract and refractive surgery.

[15]  Munish Sharma,et al.  Effect of inferior‐segment Intacs with and without C3‐R on keratoconus , 2007, Journal of cataract and refractive surgery.

[16]  C. Mazzotta,et al.  Corneal crosslinking: Riboflavin concentration in corneal stroma exposed with and without epithelium , 2009, Journal of cataract and refractive surgery.

[17]  R. Adelman,et al.  Risk factors for progression to penetrating keratoplasty in patients with keratoconus. , 2004, American journal of ophthalmology.

[18]  H. Oxlund,et al.  Biomechanical properties of keratoconus and normal corneas. , 1980, Experimental eye research.

[19]  C. Mazzotta,et al.  Corneal healing after riboflavin ultraviolet-A collagen cross-linking determined by confocal laser scanning microscopy in vivo: early and late modifications. , 2008, American journal of ophthalmology.

[20]  Claudio Traversi,et al.  Parasurgical therapy for keratoconus by riboflavin–ultraviolet type A rays induced cross‐linking of corneal collagen: Preliminary refractive results in an Italian study , 2006, Journal of cataract and refractive surgery.

[21]  B. Redl,et al.  Gel Electrophoretic Analysis of Corneal Collagen After Photodynamic Cross-linking Treatment , 2008, Cornea.

[22]  T. Seiler,et al.  Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. , 2003, American journal of ophthalmology.

[23]  Theo Seiler,et al.  Increased resistance of crosslinked cornea against enzymatic digestion , 2004, Current eye research.

[24]  A. Proia,et al.  Histopathological Variation in Keratoconus , 1992, Cornea.